This is a clear positive for CNTX: the company secured full economic ownership of its most promising pipeline asset (CT-202) for a modest upfront cost, removing a major overhang of future milestone/royalty payments. The Phase 1 catalyst in Q3 2026 provides a near-term event to watch. However, the company's cash position and burn rate should be monitored, as the $6.5M payout will consume a meaningful portion of its cash runway.
Price Chart
Executive Summary
Context Therapeutics amended its license agreement with BioAtla for CT-202, buying out all future milestone and royalty obligations for a total of $6.5 million ($4.5M upfront, $2.0M by Aug 1, 2026). In exchange, Context receives a royalty-free, fully paid-up, non-terminable exclusive license to CT-202, eliminating BioAtla's termination rights and Context's development/reporting obligations. Phase 1 initiation for CT-202 is expected in Q3 2026.
Key Financial Metrics
Key Facts
- Context pays BioAtla $4.5M within 5 business days and $2.0M by August 1, 2026 to buy out all future milestones and royalties on CT-202.
- License becomes irrevocable, royalty-free, fully paid-up, and non-terminable.
- BioAtla's termination rights and Context's development/reporting obligations are eliminated.
- Phase 1 clinical trial for CT-202 expected to initiate in Q3 2026.
- CT-202 is a Nectin-4 x CD3 T cell engager targeting solid tumors (bladder, colorectal, lung, breast).
- Market cap is ~$198M; total buyout cost of $6.5M represents ~3.3% of market cap.
Financial Impact
Total buyout cost of $6.5M (3.3% of $198M market cap) eliminates all future milestone and royalty obligations, potentially worth tens to hundreds of millions in contingent payments.
Risk Factors
- CT-202 is still in pre-Phase 1 development; clinical failure would render the buyout worthless.
- The $6.5M cash outlay reduces Context's cash runway, potentially requiring future financing.
- BioAtla retains patent prosecution control; any patent challenges could impact CT-202's value.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 press releases from GlobeNewswire.
| Document | Accession Number |
|---|---|
| 8-K Filing (CNTX) — Batch item 1 | 0001628280-26-035793 |
| Exhibit: exhibit99105182026bioatlal.htm | 0001628280-26-035793 |
| Document: cntx-20260514.htm | press-3296452 |
| Document: 0001628280-26-035793-index-headers.html | press-3296452 |
| Document: 0001628280-26-035793-index.html | press-3296452 |
| Document: 0001628280-26-035793.txt | press-3296452 |
| PRESS-RELEASE Data (Synthetic) | press-3296452 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 15, 2026 19w ago | 8-K | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2350 (−65.40%) |
Jun 15, 2026 19w ago | Press Release | $0.6791 $0.6299 | ▼ −7.24% | ▼ −5.86% | $0.2350 (−65.40%) |
May 18, 2026 23w ago | PRESS-RELEASE / 8-K | $2.15 $2.63 | ▲ +22.33% | ▲ +20.71% | $0.2350 (−89.07%) |
May 6, 2026 24w ago | Press Release | $2.33 $2.36 | ▲ +1.29% | ▼ −0.22% | $0.2350 (−89.91%) |
May 1, 2026 25w ago | 8-K | $2.30 $2.39 | ▲ +3.91% | ▲ +0.98% | $0.2350 (−89.78%) |
Apr 2, 2026 29w ago | 8-K | $2.72 $2.49 | ▼ −8.46% | ▼ −12.07% | $0.2350 (−91.36%) |
Mar 23, 2026 31w ago | Press Release | $3.18 $2.62 | ▼ −17.61% | ▼ −17.19% | $0.2350 (−92.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers